ATE506987T1 - Il-27 et il-2 pour le traitement du cancer - Google Patents

Il-27 et il-2 pour le traitement du cancer

Info

Publication number
ATE506987T1
ATE506987T1 AT03814878T AT03814878T ATE506987T1 AT E506987 T1 ATE506987 T1 AT E506987T1 AT 03814878 T AT03814878 T AT 03814878T AT 03814878 T AT03814878 T AT 03814878T AT E506987 T1 ATE506987 T1 AT E506987T1
Authority
AT
Austria
Prior art keywords
traitement
pour
cancer
methods
immune
Prior art date
Application number
AT03814878T
Other languages
English (en)
Inventor
Rene De Waal Malefyt
Marilyn Travis
Elena Vaisberg-Targulian
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ATE506987T1 publication Critical patent/ATE506987T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
AT03814878T 2002-12-31 2003-12-18 Il-27 et il-2 pour le traitement du cancer ATE506987T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43751502P 2002-12-31 2002-12-31
PCT/US2003/040569 WO2004060291A2 (en) 2002-12-31 2003-12-18 Uses of mammalian cytokine; related reagents

Publications (1)

Publication Number Publication Date
ATE506987T1 true ATE506987T1 (de) 2011-05-15

Family

ID=32713193

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03814878T ATE506987T1 (de) 2002-12-31 2003-12-18 Il-27 et il-2 pour le traitement du cancer

Country Status (10)

Country Link
US (3) US7445779B2 (de)
EP (1) EP1589998B1 (de)
JP (1) JP4727995B2 (de)
AT (1) ATE506987T1 (de)
AU (1) AU2003301114B2 (de)
CA (1) CA2511838C (de)
DE (1) DE60336930D1 (de)
MX (1) MXPA05007129A (de)
NZ (1) NZ579795A (de)
WO (1) WO2004060291A2 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001029070A2 (en) * 1999-10-20 2001-04-26 Genentech, Inc. Modulation of t cell differentiation for the treatment of t helper cell mediated diseases
US7393532B1 (en) * 2000-10-18 2008-07-01 Genentech, Inc. Modulation of T cell differentiation for the treatment of T helper cell mediated diseases
CN1942201B (zh) * 2004-02-17 2012-06-20 先灵公司 调节il-23活性的方法；相关试剂
US20050214296A1 (en) * 2004-02-17 2005-09-29 Schering Corporation Methods of modulating cytokine activity; related reagents
AU2005241020B2 (en) * 2004-05-03 2008-07-10 Merck Sharp & Dohme Corp. Use of IL-17 expression to predict skin inflammation; methods of treatment
US20050287593A1 (en) 2004-05-03 2005-12-29 Schering Corporation Use of cytokine expression to predict skin inflammation; methods of treatment
EP1828250A2 (de) * 2004-12-16 2007-09-05 Genentech, Inc. Methoden zur behandlung von autoimmunkrankheiten
JP4839434B2 (ja) * 2005-03-14 2011-12-21 千葉県 ｐ２８分子またはその遺伝子を含む医薬製剤
DE102005049800B4 (de) * 2005-10-18 2009-09-17 Johannes-Gutenberg-Universität Mainz Verfahren zur Auffindung von Inhibitoren des Epstein-Barr-Virus-induzierten Gens 3 (EBI 3) und deren Verwendungen bei der Behandlung von metastasierenden Tumoren und allergischem Asthma
JP2009540018A (ja) 2006-06-13 2009-11-19 ザイモジェネティクス， インコーポレイテッド Ｉｌ−１７およびｉｌ−２３アンタゴニストならびにその使用方法
CA2662862A1 (en) * 2006-08-25 2008-02-28 Zymogenetics, Inc. Treatment of aplastic anemia
WO2008115597A2 (en) * 2007-03-21 2008-09-25 Cytologic, Inc. Cytokine muteins and methods for enhancing immune responses in mammals
CA2706425A1 (en) 2007-11-27 2009-06-04 Ablynx N.V. Method for obtaining polypeptide constructs comprising two or more single domain antibodies
US9205131B2 (en) * 2011-03-30 2015-12-08 The Regents Of The University Of California Use of IL-17D for the treatment and prevention of cancers
EP2700409A1 (de) * 2012-08-23 2014-02-26 Deutsches Rheuma-Forschungszentrum Berlin IL-27 zur Modulation einer Immunreaktion bei akuter Lungenerkrankung
BR112015026019A2 (pt) 2013-04-11 2017-07-25 Brigham & Womens Hospital Inc métodos e composições de tratamento de doenças autoimunes
WO2015157561A1 (en) * 2014-04-09 2015-10-15 La Jolla Institute For Allergy And Immunology Specific and unique t cell responses and molecular signatures for treatment and diagnosis of mycobacterium tuberculosis
CN105713876A (zh) * 2016-03-29 2016-06-29 深圳爱生再生医学科技有限公司 Cik细胞培养基及其应用
CN106754700A (zh) * 2016-12-23 2017-05-31 西安东澳生物科技有限公司 一种抗肿瘤过继免疫活性细胞cik的制备方法
KR102625293B1 (ko) * 2017-03-06 2024-01-15 알토 바이오사이언스 엘엘씨 Il-12 및 il-18로의 il-15-기반 융합
KR102265437B1 (ko) 2017-11-24 2021-06-15 의료법인 성광의료재단 Nk 배양용 조성물 및 이를 이용하여 nk 세포를 배양하는 방법
CN120463807A (zh) 2018-03-22 2025-08-12 表面肿瘤学有限责任公司 抗il-27抗体及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7148330B2 (en) * 1999-07-30 2006-12-12 Schering Corporation Binding compounds for IL-27
US20020160502A1 (en) * 2000-09-26 2002-10-31 Roger Williams Hospital Recombinant BCG vaccines for the prevention and treatment of cancer
WO2002032374A2 (en) * 2000-10-18 2002-04-25 Immunex Corporation Methods for treating il-18 mediated disorders
IL140537A0 (en) * 2000-12-25 2002-02-10 Hadasit Med Res Service Educated nk t cells and their uses in the treatment of immune-related disorders

Also Published As

Publication number Publication date
EP1589998A2 (de) 2005-11-02
US20040219096A1 (en) 2004-11-04
DE60336930D1 (de) 2011-06-09
WO2004060291A2 (en) 2004-07-22
EP1589998A4 (de) 2007-11-07
US8178308B2 (en) 2012-05-15
US20070224166A1 (en) 2007-09-27
CA2511838A1 (en) 2004-07-22
JP2006514057A (ja) 2006-04-27
AU2003301114B2 (en) 2010-03-18
AU2003301114A1 (en) 2004-07-29
EP1589998B1 (de) 2011-04-27
WO2004060291A3 (en) 2005-03-17
NZ579795A (en) 2011-03-31
MXPA05007129A (es) 2005-08-26
US20120225030A1 (en) 2012-09-06
JP4727995B2 (ja) 2011-07-20
CA2511838C (en) 2014-05-06
US7445779B2 (en) 2008-11-04

Similar Documents

Publication Publication Date Title
DE60336930D1 (de) IL-27 et IL-2 pour le traitement du cancer
EP2283860A3 (de) Verwendung für interleukin-33 und den il-33 rezeptorkomplex
ZA202203254B (en) Immunocytokine comprising heterodimeric protein complex based on il-15/il-15rα
MX2025003080A (es) Conjugados de il-15, y sus usos
MY206158A (en) Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer
DE60031248D1 (de) Elektroaktive pore
WO2005079848A3 (en) Agonists and antagonists of p28 ebi3 and wsx/tccr for treating immune disorders
WO2005000215A3 (en) Methods for treating pain
MXPA05010035A (es) Tratamiento de desordenes inmunologicos usando agonistas de interleucina-21/receptor de interleucina-21.
MY169308A (en) Treatment of tnf? related disorders
GB0209891D0 (en) Novel compounds
EP1567155A4 (de) Verabreichung teilgereifterdendritischer zellen in vitro zur behandlung von tumoren
IT1317835B1 (it) Citochine modificate per uso nella terapia del cancro.
MY135829A (en) Analeptic and drug combinations
MX2024012582A (es) Composiciones farmaceuticas de proteinas terapeuticas y metodos de uso
DK0572537T3 (da) Cytokinnhibitorer
MX2024009593A (es) Formas solidas de 1-((s)-4-((r)-7-(6-amino-4-metil-3-(trifluoromet il)piridin-2-il)-6-cloro-8-fluoro-2-(((s)-1-metilpirrolidin-2-il) metoxi)quinazolin-4-il)-3-metilpiperazin-1-il)prop-2-en-1-ona.
DE69428460D1 (de) Chemotaktisches protein
ATE431742T1 (de) Modifizierte zytokine für krebs therapie
ATE469659T1 (de) Stibogluconate-natrium und il-2 zur krebsbehandlung
WO2001023522A3 (en) Compositions and methods for p53-mediated repression of gene expression
AU1592801A (en) Methods of treating inflammatory bowel disease using cholera toxin B subunit
DK1017377T3 (da) Anvendelse af 6,7-substituerede 2-aminotetraliner til behandling af af cytokin fremkaldte inflammatoriske tilstande
CY1116323T1 (el) ΘΕΡΑΠΕΥΤΙΚΗ ΑΓΩΓΗ TNFα-ΣΧΕΤΙΖΟΜΕΝΩΝ ΔΙΑΤΑΡΑΧΩΝ
AU2013204153A1 (en) Treatment of TNFalpha related disorders

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties